Vical Leaves Gene Therapy for Vaccines
Executive Summary
Is gene therapy ever going to become a routine, reliable method of disease treatment? It appears that the odds of success in anything like the near term are slimming. Now one of the first companies to get involved in gene therapy is finally giving up on it: San Diego-based Vical Inc., founded in 1987, recently announced its intention to use its naked DNA technology to develop a vaccine for cytomegalovirus (CMV).
You may also be interested in...
Austrianova FSG Biotechnologie GMBH
Austrianova is pursuing both cell- and retroviral gene-therapy technologies to treat cancer. The Vienna-based company's most advanced project is a cell-therapy designed to treat pancreatic cancer which has gained Orphan Drug status in Europe.
Can Electroporation Revive Gene Therapy?
As regulators increase their scrutiny of viral vectors for gene therapy and set the bars for safety ever higher, some industry observers have begun questioning whether gene therapy will ever become a commercial reality. The difficulties in the field may turn out to be a life-saver for MaxCyte Inc. Its managers think their flow electroporation technology could be a platform for transforming patients' cells and getting them to produce a desired protein--without viruses, and the risks they bring.
Can Electroporation Revive Gene Therapy?
As regulators increase their scrutiny of viral vectors for gene therapy and set the bars for safety ever higher, some industry observers have begun questioning whether gene therapy will ever become a commercial reality. The difficulties in the field may turn out to be a life-saver for MaxCyte Inc. Its managers think their flow electroporation technology could be a platform for transforming patients' cells and getting them to produce a desired protein--without viruses, and the risks they bring.